Metastatic Triple Negative Breast Cancer Clinical Trials

35 clinical trials for Metastatic Triple Negative Breast Cancer across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer — RECRUITING · PHASE2
• The TASTY-steering Study — RECRUITING · NA
• Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) — RECRUITING · PHASE1
• Saci Nivo Rela for TNBC — RECRUITING · PHASE1
• The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer. — RECRUITING · PHASE2
• An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC) — NOT_YET_RECRUITING · PHASE1
• Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. — ACTIVE_NOT_RECRUITING · PHASE2
• Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) — NOT_YET_RECRUITING · PHASE1
• A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer — NOT_YET_RECRUITING · PHASE2
• Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer — NOT_YET_RECRUITING · PHASE2
• Leflunomide in Previously Treated Metastatic Triple Negative Cancers — COMPLETED · PHASE1
• A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments — ACTIVE_NOT_RECRUITING · PHASE2
• Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer — COMPLETED · NA
• Olinvacimab With Pembrolizumab in Patients With mTNBC — TERMINATED · PHASE2
• Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer — COMPLETED · PHASE2
• SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC — COMPLETED · PHASE2
• Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases — COMPLETED · PHASE1
• Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer — OTHER · PHASE2
• L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients — COMPLETED · PHASE1
• Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer — COMPLETED · PHASE2
• TIP in Patients Affected by Metastatic TNBC — OTHER
• Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer — OTHER · PHASE1
• P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC . — WITHDRAWN · PHASE2
• Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer — OTHER · PHASE2
• Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) — COMPLETED · PHASE3
• S 81694 Plus Paclitaxel in Metastatic Breast Cancer — COMPLETED · PHASE1
• Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile — SUSPENDED
• Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer — COMPLETED · PHASE2
• Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer — TERMINATED · PHASE3
• A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer — WITHDRAWN · PHASE2
• Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors — WITHDRAWN · NA
• Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer — COMPLETED · PHASE1

Refine this search